Phase I/II study of TTI-622 in combination with azacitidine in first line p53 mutant acute myeloid leukemia patients
Latest Information Update: 04 May 2021
At a glance
- Drugs Azacitidine (Primary) ; Maplirpacept (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Trillium Therapeutics
- 04 May 2021 New trial record
- 28 Apr 2021 According to a Trillium Therapeutics media release, this study is open for enrollment, and the company expect the first patients to be dosed this quarter.